Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCELERATE: Platform Protocol for Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
NCT06859424Phase 2Recruiting
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept, ruxolitinib in graft-versus-host disease (GVHD), sponsored by Center for International Blood and Marrow Transplant Research. Started Jul 2025; status: recruiting.
02
Drugs
abataceptruxolitinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06859424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859424.